Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omburtamab Lu 177 - Y-mAbs Therapeutics

Next Previous
Drug Profile

Omburtamab Lu 177 - Y-mAbs Therapeutics

Alternative Names: 177Lu-DTPA-omburtamab; 177Lu-omburtamab-DTPA; DPTA-omburtamab; Omburtamab-DPTA; Radiolabeled DPTA-omburtamab

Latest Information Update: 28 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Y-mAbs Therapeutics
  • Class Antineoplastics; Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceuticals
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Medulloblastoma; Meningeal carcinomatosis
  • No development reported Solid tumours

Most Recent Events

  • 28 Jun 2023 No recent reports of development identified for preclinical development in Solid-tumours(Diagnosis) in USA (Intraventricular)
  • 11 Aug 2022 Y-mAbs Therapeutics terminates phase-I/II trial in Medulloblastoma (In adolescents, In children, Recurrent, Second-line therapy or greater, In adults) in USA, United Kingdom and Denmark (Intraventricular) due to business priorities (NCT04167618) (EudraCT2020-000670-22)
  • 15 Jul 2022 Y-mAbs Therapeutics withdraws a phase I/II trial prior to enrolment for Meningeal carcimatosis in US and UK due to business priorities (NCT04315246)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top